Ethanol ablation guided by sonographic appearance of the nodule is effective for treatment of primary hyperparathyroidism in dogs.

Ultrasound-guided ethanol ablation effectively treats canine primary hyperparathyroidism with 89% success and acceptable safety.

This prospective observational study evaluated ultrasound-guided ethanol ablation for treating primary hyperparathyroidism in dogs. Forty-nine dogs with confirmed primary hyperparathyroidism underwent percutaneous ethanol ablation, guided by real-time sonographic appearance (diffuse intralesional hyperechogenicity) rather than predetermined volumes. Hypercalcemia resolved in 42 of 47 dogs (89.4%) with complete follow-up data. Dogs achieving resolution received significantly greater median ethanol volumes (0.60 mL vs 0.15 mL). Complications occurred in 12 dogs (25.5%), with 10 classified as minor and 2 as major. Notably, ethanol volume was not associated with increased complication rates or ethanol leakage severity. The authors concluded that sonographically guided ethanol ablation represents an effective and relatively safe minimally invasive alternative to surgical parathyroidectomy, with the advantage of using real-time imaging feedback rather than fixed-volume protocols. This technique may improve clinical outcomes while reducing procedural morbidity in dogs with primary hyperparathyroidism.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.